Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has begun a program to determine the 3-dimensional structure of NR2F6 both with and without the Company’s proprietary small molecule drugs bound to it. The Company recently reported that it has identified key structural elements in small molecules that make them active and specific towards the NR2F6 target. The object of this structure-determination program is to shed light on exactly how the small molecules bind to and modulate NR2F6 activity.